Mikrovaskuläre Komplikationen bei Typ-2-Diabetes (Investigativ)

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?

Not FDA-cleared for diabetic microvascular complications. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational with anecdotal case-report support only.

Welche Evidenz existiert?

Tier C (investigational). Only anecdotal Eastern European case reports describe modest neuropathic symptom reduction and improved skin perfusion after lower-extremity hirudotherapy. There are no controlled trials. Evidence-based management of diabetic microvascular disease is multifaceted: glycemic control to an individualized HbA1c target, blood pressure under 130/80, ACE inhibitor or ARB for nephroprotection, statin therapy, foot care, retinal screening, and disease-specific interventions (gabapentinoids or duloxetine for painful neuropathy, intravitreal anti-VEGF for proliferative retinopathy). Critical safety: diabetic foot syndrome with neuropathy is a high-risk site for non-healing wounds.

Hauptrisiken

• Bleeding from bite sites for 6 to 24 hours after detachment
• Slow or impaired bite-wound healing in diabetic patients
• Higher risk of local skin infection given diabetes-related impaired immunity
• Aeromonas hydrophila infection
• Worsening of any neuropathy-related pressure injury at the bite location
• Allergic reaction to leech saliva
• Catastrophic risk if a practitioner places a leech on a diabetic foot — this is contraindicated
• Delay of evidence-based glycemic control, blood pressure management, ACE inhibitor/ARB, statin, and disease-specific therapy

Wer dies nicht in Betracht ziehen sollte

• Patients with active diabetic foot ulcer or Charcot foot
• Patients with severe peripheral neuropathy and loss of protective sensation
• Patients on antiplatelet therapy
• Patients with HbA1c over 9 percent (optimize glycemic control first)
• Patients with active retinal hemorrhage or proliferative retinopathy not yet treated
• Patients with peripheral vascular disease and reduced ankle-brachial index
• Patients on anticoagulants or with severe anemia

Was Sie Ihren Kliniker fragen sollten

• What is my current HbA1c, blood pressure, and ankle-brachial index?
• Have I had a retinal exam, kidney function assessment, and foot exam this year?
• Am I on an ACE inhibitor or ARB and a statin per guideline?
• What evidence-based therapy is available for my specific complication (neuropathy, retinopathy, nephropathy)?
• Where exactly will the leech be placed — confirm NEVER on the foot or any insensate area?
• What is the wound-care plan if the bite site does not heal as expected?

Wann dringende medizinische Versorgung suchen

• New ulcer, blister, or breakdown of skin on the foot
• Black, purple, or non-blanching discoloration of any toe
• Spreading redness, warmth, pus, or red streaks at any bite or wound site
• Fever above 38.0 C / 100.4 F or chills
• Sudden vision change, floaters, or curtain-like visual loss
• Symptoms of hypoglycemia or hyperglycemia not responding to usual management